DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.

By J. D. de Kok, G. Verhaegh, R. Roelofs, D. Hessels, L. Kiemeney, T. Aalders, D. Swinkels, J. Schalken. Cancer Research, 2002

662 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Long noncoding RNAs: functional surprises from the RNA world. (2009, background): “…ncRNAs are misregulated in various diseases, especially cancer (for review, see Costa 2005; Prasanth and Spector 2007), and some have been found to 1500 GENES & DEVELOPMENT be very sensitive and specific markers of tumors, such as DD3 (also known as PCA3) in prostate tumors (de Kok et al. 2002).”
Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer (2009, background): “One of these has been shown to be overexpressed in PCa-PCA-3 (de Kok et al, 2002) and the other is a product of a chromosomal rearrangement, which creates a common prostate cancer-specific product, the TMPRSS2:ERG fusion (Tomlins et al, 2005).”
Circulating Long Noncoding RNA, LIPCAR, Predicts Survival in Patients With Heart Failure (2014, methodology): “A prostate-specific long intergenic noncoding RNA PCA3 in urine has been identified as the most specific biomarker for the detection of prostate cancer with higher specificity compared with the widely used prostate-specific antigen test.(7,8) The PCA3 assay has been approved for detection of prostat”